NASDAQ:VIRI Virios Therapeutics (VIRI) Stock Price, News & Analysis $1.30 -0.07 (-5.11%) As of 10/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC Filings About Virios Therapeutics Stock (NASDAQ:VIRI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virios Therapeutics alerts:Sign Up Key Stats Today's Range$1.29▼$1.3850-Day Range$1.35▼$2.6852-Week Range$0.13▼$1.04Volume110,445 shsAverage Volume1.05 million shsMarket Capitalization$25.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Virios Therapeutics, Inc. (NASDAQ: VIRI) is a clinical-stage biotechnology company focused on developing treatments for diseases associated with abnormal immune responses to latent viral infections. The company’s research has primarily centered on fibromyalgia, a chronic condition characterized by widespread pain and other symptoms. Virios Therapeutics’ lead product candidate is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory medicine. The company has evaluated IMC-1 in clinical studies for fibromyalgia and has investigated the potential role of antiviral and anti-inflammatory treatment in addressing the underlying mechanisms of the disease. Founded in 2018, Virios Therapeutics has focused its development activities on the U.S. market and on advancing therapies for conditions with significant unmet medical needs. As a clinical-stage company, its products remain subject to clinical development and regulatory review and are not broadly marketed pharmaceuticals.AI Generated. May Contain Errors. Read More Receive VIRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIRI Stock News HeadlinesVirios Therapeutics (NASDAQ:VIRI) Stock Falls 2.1% - Here's WhyOctober 14 at 2:03 AM | americanbankingnews.comDogwood Therapeutics Inc (DWTX)March 16, 2025 | investing.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 14 at 1:00 AM | Banyan Hill Publishing (Ad)Dogwood prices 578,950 shares at $8.26 in registered direct offeringMarch 13, 2025 | markets.businessinsider.comDogwood announces conversion of existing $19.5M in debt to equityMarch 12, 2025 | markets.businessinsider.comDWTX Stock trading resumesFebruary 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. (DWTX)February 2, 2025 | finance.yahoo.comDWTX Stock trading halted, volatility trading pauseJanuary 28, 2025 | markets.businessinsider.comSee More Headlines VIRI Stock Analysis - Frequently Asked Questions How have VIRI shares performed this year? Virios Therapeutics' stock was trading at $4.16 at the start of the year. Since then, VIRI stock has decreased by 68.8% and is now trading at $1.30. How were Virios Therapeutics' earnings last quarter? Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its earnings results on Thursday, August, 8th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. When did Virios Therapeutics IPO? Virios Therapeutics (VIRI) raised $30 million in an initial public offering on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Virios Therapeutics? Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virios Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Atossa Genetics (ATOS), Beyond Meat (BYND), Palantir Technologies (PLTR), SNDL (SNDL), Tiziana Life Sciences (TLSA), AMC Entertainment (AMC) and Ford Motor (F). Company Calendar Last Earnings8/08/2024Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VIRI CIK1818844 Webwww.virios.com Phone866-620-8655FaxN/AEmployees5Year Founded2012Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-130.33% Return on Assets-115.00% Debt Debt-to-Equity RatioN/A Current Ratio7.27 Quick Ratio7.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book6.50Miscellaneous Outstanding Shares19,258,000Free Float16,909,000Market Cap$25.04 million OptionableNo Data Beta1.58 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:VIRI) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
